Form 4: Halozyme Therapeutics CEO Helen Torley Reports Stock Transactions
SEC Form 4 Filing
Halozyme Therapeutics' CEO, Helen Torley, reports the vesting and settlement of restricted and performance stock units, along with associated tax withholding dispositions.
Summary
- On February 15, 2025, Helen Torley, CEO of Halozyme Therapeutics, exercised restricted stock units, acquiring 13,092 shares of common stock.
- Simultaneously, 7,098 shares were disposed of to cover tax withholding obligations at a price of $58.29 per share.
- On February 16, 2025, Torley exercised performance stock units, acquiring 71,810 shares of common stock.
- An additional 38,668 shares were disposed of on the same day for tax withholding at $58.29 per share.
- Also on February 16, 2025, Torley exercised restricted stock units, acquiring 21,009 shares of common stock.
- 11,313 shares were disposed of to cover tax withholding obligations at a price of $58.29 per share on the same day.
- Further on February 16, 2025, Torley exercised restricted stock units, acquiring 16,875 shares of common stock.
- 9,087 shares were disposed of to cover tax withholding obligations at a price of $58.29 per share on the same day.
- Following these transactions, Torley directly owns 723,364 shares of Halozyme Therapeutics common stock.
- Torley also owns 33,749 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a neutral report of stock transactions. It doesn't inherently convey positive or negative sentiment.
Positives
- The vesting of stock units indicates confidence in the company's performance.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 02/15/2025 | Vesting and settlement of restricted stock units; disposition of shares for tax withholding. |
| 02/16/2025 | Vesting and settlement of performance stock units and restricted stock units; disposition of shares for tax withholding. |
| 02/18/2025 | Date of Form 4 signature. |
Keywords
Halozyme Therapeutics, Helen Torley, stock units, Form 4, insider trading, stock options, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.